메뉴 건너뛰기




Volumn 15, Issue 23-24, 2010, Pages 1058-1069

Erratum: Heparin/heparan sulphate-based drugs (Drug Discovery Today DOI: 10.1016/j.drudis.2010.10.009);Heparin/heparan sulphate-based drugs

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; AVE 5026; DACARBAZINE; DOCETAXEL; ENOXAPARIN; EP 217609; EP 42675; EP 80061; EPRODISATE; FONDAPARINUX; GEMCITABINE; HEPARAN SULFATE; HEPARIN; HEPARIN ANTAGONIST; HOMOTAURINE; IDRAPARINUX; M 118; M 402; OTR 3; OTR 4120; PG 545; PI 88; PMX 6005; RG 1192; RGD 120; SR 123781; SSR 126517; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIVIMIND; ZP 2345;

EID: 78649633567     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.02.009     Document Type: Erratum
Times cited : (92)

References (159)
  • 1
    • 0034937128 scopus 로고    scopus 로고
    • Role of glycosaminoglycans in inflammation
    • Lever R., et al. Role of glycosaminoglycans in inflammation. Inflammopharmacology 2001, 9:165-169.
    • (2001) Inflammopharmacology , vol.9 , pp. 165-169
    • Lever, R.1
  • 2
    • 33748048179 scopus 로고    scopus 로고
    • The role of heparan sulphate in inflammation
    • Parish C.R. The role of heparan sulphate in inflammation. Nat. Rev. Immunol. 2006, 6:633-643.
    • (2006) Nat. Rev. Immunol. , vol.6 , pp. 633-643
    • Parish, C.R.1
  • 3
    • 24944586023 scopus 로고    scopus 로고
    • Heparan sulfate and inflammation
    • Parish C.R. Heparan sulfate and inflammation. Nat. Immunol. 2005, 6:861-862.
    • (2005) Nat. Immunol. , vol.6 , pp. 861-862
    • Parish, C.R.1
  • 4
    • 0035997236 scopus 로고    scopus 로고
    • Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases
    • Díaz-Nido J., et al. Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides 2002, 23:1323-1332.
    • (2002) Peptides , vol.23 , pp. 1323-1332
    • Díaz-Nido, J.1
  • 5
    • 0034904186 scopus 로고    scopus 로고
    • Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena
    • Iozzo R.V., San Antonio J.D. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J. Clin. Invest. 2001, 108:349-355.
    • (2001) J. Clin. Invest. , vol.108 , pp. 349-355
    • Iozzo, R.V.1    San Antonio, J.D.2
  • 6
    • 0030973187 scopus 로고    scopus 로고
    • Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated?
    • Rosenberg R.D., et al. Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated?. J. Clin. Invest. 1997, 99:2062-2070.
    • (1997) J. Clin. Invest. , vol.99 , pp. 2062-2070
    • Rosenberg, R.D.1
  • 7
    • 33749558133 scopus 로고    scopus 로고
    • Therapeutic value of glycosaminoglycans in cancer
    • Yip G.W., et al. Therapeutic value of glycosaminoglycans in cancer. Mol. Cancer Ther. 2006, 5:2139-2148.
    • (2006) Mol. Cancer Ther. , vol.5 , pp. 2139-2148
    • Yip, G.W.1
  • 8
    • 0031023713 scopus 로고    scopus 로고
    • Microbial adherence to and invasion through proteoglycans
    • Rostand K.S., Esko J.D. Microbial adherence to and invasion through proteoglycans. Infect. Immun. 1997, 65:1-8.
    • (1997) Infect. Immun. , vol.65 , pp. 1-8
    • Rostand, K.S.1    Esko, J.D.2
  • 9
    • 0029549804 scopus 로고    scopus 로고
    • Protein-glycosaminoglycan interactions: infectiological aspects
    • Sawitzky D. Protein-glycosaminoglycan interactions: infectiological aspects. Med. Microbiol. Immunol. (Berl.) 1996, 184:155-161.
    • (1996) Med. Microbiol. Immunol. (Berl.) , vol.184 , pp. 155-161
    • Sawitzky, D.1
  • 10
    • 0032788960 scopus 로고    scopus 로고
    • Glycosaminoglycan-binding microbial proteins in tissue adhesion and invasion: key events in microbial pathogenicity
    • Wadstrom T., Ljungh A.S.A. Glycosaminoglycan-binding microbial proteins in tissue adhesion and invasion: key events in microbial pathogenicity. J. Med. Microbiol. 1999, 48:223-233.
    • (1999) J. Med. Microbiol. , vol.48 , pp. 223-233
    • Wadstrom, T.1    Ljungh, A.S.A.2
  • 11
    • 56649100319 scopus 로고    scopus 로고
    • The structure of glycosaminoglycans and their interactions with proteins
    • Gandhi N.S., Mancera R.L. The structure of glycosaminoglycans and their interactions with proteins. Chem. Biol. Drug Des. 2008, 72:455-482.
    • (2008) Chem. Biol. Drug Des. , vol.72 , pp. 455-482
    • Gandhi, N.S.1    Mancera, R.L.2
  • 12
    • 21744431575 scopus 로고    scopus 로고
    • The sweet and sour of cancer: glycans as novel therapeutic targets
    • Fuster M.M., Esko J.D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 2005, 5:526-542.
    • (2005) Nat. Rev. Cancer , vol.5 , pp. 526-542
    • Fuster, M.M.1    Esko, J.D.2
  • 13
    • 36849092506 scopus 로고    scopus 로고
    • Glycan antagonists and inhibitors: a fount for drug discovery
    • Brown J.R., et al. Glycan antagonists and inhibitors: a fount for drug discovery. Crit. Rev. Biochem. Mol. Biol. 2007, 42:481-515.
    • (2007) Crit. Rev. Biochem. Mol. Biol. , vol.42 , pp. 481-515
    • Brown, J.R.1
  • 14
    • 6444222045 scopus 로고    scopus 로고
    • Glycomics: a pathway to a class of new and improved therapeutics
    • Shriver Z., et al. Glycomics: a pathway to a class of new and improved therapeutics. Nat. Rev. Drug Discov. 2004, 3:863-873.
    • (2004) Nat. Rev. Drug Discov. , vol.3 , pp. 863-873
    • Shriver, Z.1
  • 15
    • 3042695376 scopus 로고    scopus 로고
    • Carbohydrate-based therapeutics
    • Osborn H.M.I., et al. Carbohydrate-based therapeutics. J. Pharm. Pharmacol. 2004, 56:691-702.
    • (2004) J. Pharm. Pharmacol. , vol.56 , pp. 691-702
    • Osborn, H.M.I.1
  • 16
    • 33845521471 scopus 로고    scopus 로고
    • Glycomic approaches toward drug development: therapeutically exploring the glycosaminoglycanome
    • Gesslbauer B., Kungl A.J. Glycomic approaches toward drug development: therapeutically exploring the glycosaminoglycanome. Curr. Opin. Mol. Ther. 2006, 8:521-528.
    • (2006) Curr. Opin. Mol. Ther. , vol.8 , pp. 521-528
    • Gesslbauer, B.1    Kungl, A.J.2
  • 17
    • 33745040961 scopus 로고    scopus 로고
    • Therapeutic applications of glycosaminoglycans
    • Volpi N. Therapeutic applications of glycosaminoglycans. Curr. Med. Chem. 2006, 13:1799-1810.
    • (2006) Curr. Med. Chem. , vol.13 , pp. 1799-1810
    • Volpi, N.1
  • 18
    • 34447512941 scopus 로고    scopus 로고
    • Heparan sulfate-protein interactions: a concept for drug design?
    • Lindahl U. Heparan sulfate-protein interactions: a concept for drug design?. Thromb. Haemost. 2007, 98:109-115.
    • (2007) Thromb. Haemost. , vol.98 , pp. 109-115
    • Lindahl, U.1
  • 19
    • 0642346833 scopus 로고    scopus 로고
    • The potential of the molecular diversity of heparin and heparan sulfate for drug development
    • Fugedi P. The potential of the molecular diversity of heparin and heparan sulfate for drug development. Mini Rev. Med. Chem. 2003, 3:659-667.
    • (2003) Mini Rev. Med. Chem. , vol.3 , pp. 659-667
    • Fugedi, P.1
  • 22
    • 33645468255 scopus 로고    scopus 로고
    • Emerging anticoagulants: mechanism of action and future potential
    • Klement P., Rak J. Emerging anticoagulants: mechanism of action and future potential. Vnitr. Lek. 2006, 52(Suppl. 1):119-122.
    • (2006) Vnitr. Lek. , vol.52 , Issue.SUPPL. 1 , pp. 119-122
    • Klement, P.1    Rak, J.2
  • 23
    • 0036283477 scopus 로고    scopus 로고
    • Selective inhibition of coagulation factors: advances in antithrombotic therapy
    • Bauer K.A. Selective inhibition of coagulation factors: advances in antithrombotic therapy. Semin. Thromb. Hemost. 2002, 28(Suppl. 2):15-24.
    • (2002) Semin. Thromb. Hemost. , vol.28 , Issue.SUPPL. 2 , pp. 15-24
    • Bauer, K.A.1
  • 24
    • 19744372264 scopus 로고    scopus 로고
    • Synthetic heparin derivatives as new anticoagulant drugs
    • De Kort M., et al. Synthetic heparin derivatives as new anticoagulant drugs. Drug Discov. Today 2005, 10:769-779.
    • (2005) Drug Discov. Today , vol.10 , pp. 769-779
    • De Kort, M.1
  • 25
    • 40149097733 scopus 로고    scopus 로고
    • Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles
    • Alban S. Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles. Hamostaseologie 2008, 28:51-61.
    • (2008) Hamostaseologie , vol.28 , pp. 51-61
    • Alban, S.1
  • 26
    • 0022368634 scopus 로고
    • Contribution of monosaccharide residues in heparin binding to antithrombin III
    • Atha D.H., et al. Contribution of monosaccharide residues in heparin binding to antithrombin III. Biochemistry 1985, 24:6723-6729.
    • (1985) Biochemistry , vol.24 , pp. 6723-6729
    • Atha, D.H.1
  • 27
    • 0041494802 scopus 로고
    • Multiple functional domains of the heparin molecule
    • Oosta G.M., et al. Multiple functional domains of the heparin molecule. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:829-833.
    • (1981) Proc. Natl. Acad. Sci. U. S. A. , vol.78 , pp. 829-833
    • Oosta, G.M.1
  • 28
    • 4544280219 scopus 로고    scopus 로고
    • A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew
    • Petitou M., v Boeckel C.A.A. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew. Chem. Int. Ed. Engl. 2004, 43:3118-3133.
    • (2004) Chem. Int. Ed. Engl. , vol.43 , pp. 3118-3133
    • Petitou, M.1    v Boeckel, C.A.A.2
  • 29
    • 33748233635 scopus 로고
    • The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics
    • Van Boeckel C.A.A., Petitou M. The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew. Chem. Int. Ed. Engl. 1993, 32:1671-1690.
    • (1993) Angew. Chem. Int. Ed. Engl. , vol.32 , pp. 1671-1690
    • Van Boeckel, C.A.A.1    Petitou, M.2
  • 30
    • 0037507303 scopus 로고    scopus 로고
    • Antithrombin III phenylalanines 122 and 121 contribute to its high affinity for heparin and its conformational activation
    • Jairajpuri M.A., et al. Antithrombin III phenylalanines 122 and 121 contribute to its high affinity for heparin and its conformational activation. J. Biol. Chem. 2003, 278:15941-15950.
    • (2003) J. Biol. Chem. , vol.278 , pp. 15941-15950
    • Jairajpuri, M.A.1
  • 31
    • 70449598272 scopus 로고    scopus 로고
    • From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile
    • Petitou M., et al. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Thromb. Haemost. 2009, 102:804-810.
    • (2009) Thromb. Haemost. , vol.102 , pp. 804-810
    • Petitou, M.1
  • 32
    • 0141886345 scopus 로고    scopus 로고
    • Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties
    • Avci F.Y., et al. Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties. Curr. Pharm. Des. 2003, 9:2323-2335.
    • (2003) Curr. Pharm. Des. , vol.9 , pp. 2323-2335
    • Avci, F.Y.1
  • 33
    • 3042857728 scopus 로고    scopus 로고
    • Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy
    • Turpie A.G.G. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy. Expert Opin. Pharmacother. 2004, 5:1373-1384.
    • (2004) Expert Opin. Pharmacother. , vol.5 , pp. 1373-1384
    • Turpie, A.G.G.1
  • 34
    • 67650422376 scopus 로고    scopus 로고
    • Discontinued drugs in 2008: cardiovascular drugs
    • Xu-song Z., Bing-ren X. Discontinued drugs in 2008: cardiovascular drugs. Expert Opin. Investig. Drugs 2009, 18:875-885.
    • (2009) Expert Opin. Investig. Drugs , vol.18 , pp. 875-885
    • Xu-song, Z.1    Bing-ren, X.2
  • 35
    • 2642617786 scopus 로고    scopus 로고
    • Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide
    • Herbert J.M., et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998, 91:4197-4205.
    • (1998) Blood , vol.91 , pp. 4197-4205
    • Herbert, J.M.1
  • 36
    • 33947422061 scopus 로고    scopus 로고
    • High affinity interaction between a synthetic, highly negatively charged pentasaccharide and alpha- or beta-antithrombin is predominantly due to nonionic interactions
    • Hjelm R., Schedin-Weiss S. High affinity interaction between a synthetic, highly negatively charged pentasaccharide and alpha- or beta-antithrombin is predominantly due to nonionic interactions. Biochemistry 2007, 46:3378-3384.
    • (2007) Biochemistry , vol.46 , pp. 3378-3384
    • Hjelm, R.1    Schedin-Weiss, S.2
  • 37
    • 0032530648 scopus 로고    scopus 로고
    • Mechanism of heparin activation of antithrombin: evidence for an induced-fit model of allosteric activation involving two interaction subsites
    • Desai U.R., et al. Mechanism of heparin activation of antithrombin: evidence for an induced-fit model of allosteric activation involving two interaction subsites. Biochemistry 1998, 37:13033-13041.
    • (1998) Biochemistry , vol.37 , pp. 13033-13041
    • Desai, U.R.1
  • 38
    • 0032571333 scopus 로고    scopus 로고
    • Mechanism of heparin activation of antithrombin: role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin
    • Desai U.R., et al. Mechanism of heparin activation of antithrombin: role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin. J. Biol. Chem. 1998, 273:7478-7487.
    • (1998) J. Biol. Chem. , vol.273 , pp. 7478-7487
    • Desai, U.R.1
  • 39
    • 0028545446 scopus 로고
    • Feasible synthesis and biological properties of six 'non-glycosamino' glycan analogues of the antithrombin III binding heparin pentasaccharide
    • Westerduin P., et al. Feasible synthesis and biological properties of six 'non-glycosamino' glycan analogues of the antithrombin III binding heparin pentasaccharide. Bioorg. Med. Chem. 1994, 2:1267-1280.
    • (1994) Bioorg. Med. Chem. , vol.2 , pp. 1267-1280
    • Westerduin, P.1
  • 40
    • 0026441489 scopus 로고
    • Biologically active heparin-like fragments with a " non-glycosamino" glycan structure. Part 2: a tetra-o-methylated pentasaccharide with high affinity for antithrombin III
    • Basten J., et al. Biologically active heparin-like fragments with a " non-glycosamino" glycan structure. Part 2: a tetra-o-methylated pentasaccharide with high affinity for antithrombin III. Bioorg. Med. Chem. Lett. 1992, 2:901-904.
    • (1992) Bioorg. Med. Chem. Lett. , vol.2 , pp. 901-904
    • Basten, J.1
  • 41
    • 0031445112 scopus 로고    scopus 로고
    • The anticoagulant activation of antithrombin by heparin
    • Jin L., et al. The anticoagulant activation of antithrombin by heparin. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:14683-14688.
    • (1997) Proc. Natl. Acad. Sci. U. S. A. , vol.94 , pp. 14683-14688
    • Jin, L.1
  • 42
    • 0037459052 scopus 로고    scopus 로고
    • Structure of β-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity
    • McCoy A.J., et al. Structure of β-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity. J. Mol. Biol. 2003, 326:823-833.
    • (2003) J. Mol. Biol. , vol.326 , pp. 823-833
    • McCoy, A.J.1
  • 43
    • 44449100797 scopus 로고    scopus 로고
    • Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders
    • Prandoni P., et al. Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders. Expert Opin. Investig. Drugs 2008, 17:773-777.
    • (2008) Expert Opin. Investig. Drugs , vol.17 , pp. 773-777
    • Prandoni, P.1
  • 44
    • 0010851694 scopus 로고    scopus 로고
    • A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of subcutaneous SANORG 34006 in healthy male and female elderly volunteers
    • (Abstract 1547)
    • Faaij R.A., et al. A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of subcutaneous SANORG 34006 in healthy male and female elderly volunteers. Thromb. Haemost. 1999, 490-491. (Abstract 1547).
    • (1999) Thromb. Haemost. , pp. 490-491
    • Faaij, R.A.1
  • 45
    • 0010774310 scopus 로고    scopus 로고
    • A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of SANORG 34006 in healthy young male volunteers
    • (Abstract 2709)
    • Faaij R.A., et al. A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of SANORG 34006 in healthy young male volunteers. Thromb. Haemost. 1999, 853-1853. (Abstract 2709).
    • (1999) Thromb. Haemost. , pp. 853-1853
    • Faaij, R.A.1
  • 46
    • 9944251352 scopus 로고    scopus 로고
    • Idraparinux sodium
    • Ma Q., Fareed J. Idraparinux sodium. IDrugs 2004, 7:1028-1034.
    • (2004) IDrugs , vol.7 , pp. 1028-1034
    • Ma, Q.1    Fareed, J.2
  • 47
    • 0012652251 scopus 로고    scopus 로고
    • A novel long-acting synthetic factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation
    • PERSIST investigators
    • A novel long-acting synthetic factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood 2002, 100:301. PERSIST investigators.
    • (2002) Blood , vol.100 , pp. 301
  • 48
    • 19944432311 scopus 로고    scopus 로고
    • A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation
    • Buller H.R., et al. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. J. Thromb. Haemost. 2004, 2:47-53.
    • (2004) J. Thromb. Haemost. , vol.2 , pp. 47-53
    • Buller, H.R.1
  • 49
    • 19944432414 scopus 로고    scopus 로고
    • A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation
    • Minar E., Investigators T.P. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. J. Thromb. Haemost. 2004, 2:540.
    • (2004) J. Thromb. Haemost. , vol.2 , pp. 540
    • Minar, E.1    Investigators, T.P.2
  • 50
    • 34548712332 scopus 로고    scopus 로고
    • Extended prophylaxis of venous thromboembolism with idraparinux
    • Buller H.R., et al. Extended prophylaxis of venous thromboembolism with idraparinux. N. Engl. J. Med. 2007, 357:1105-1112.
    • (2007) N. Engl. J. Med. , vol.357 , pp. 1105-1112
    • Buller, H.R.1
  • 51
    • 34548768174 scopus 로고    scopus 로고
    • Idraparinux versus standard therapy for venous thromboembolic disease
    • Buller H.R., et al. Idraparinux versus standard therapy for venous thromboembolic disease. N. Engl. J. Med. 2007, 357:1094-1104.
    • (2007) N. Engl. J. Med. , vol.357 , pp. 1094-1104
    • Buller, H.R.1
  • 52
    • 42549097091 scopus 로고    scopus 로고
    • Anticoagulant effects of Idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials
    • Harenberg J., et al. Anticoagulant effects of Idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur. J. Clin. Pharmacol. 2008, 64:555-563.
    • (2008) Eur. J. Clin. Pharmacol. , vol.64 , pp. 555-563
    • Harenberg, J.1
  • 53
    • 42149173719 scopus 로고    scopus 로고
    • Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials
    • Harenberg J., et al. Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials. J. Thromb. Haemost. 2008, 6:890-892.
    • (2008) J. Thromb. Haemost. , vol.6 , pp. 890-892
    • Harenberg, J.1
  • 54
    • 78649630436 scopus 로고    scopus 로고
    • The anticoagulant Idraparinux: is the extensive half life of 60 days the cause of bleeding complications
    • Harenberg J., et al. The anticoagulant Idraparinux: is the extensive half life of 60 days the cause of bleeding complications. Br. J. Clin. Pharmacol. 2009, 68(Suppl. 1):21-121.
    • (2009) Br. J. Clin. Pharmacol. , vol.68 , Issue.SUPPL. 1 , pp. 21-121
    • Harenberg, J.1
  • 55
    • 1542359508 scopus 로고    scopus 로고
    • Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers
    • Bijsterveld N.R., et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br. J. Haematol. 2004, 124:653-658.
    • (2004) Br. J. Haematol. , vol.124 , pp. 653-658
    • Bijsterveld, N.R.1
  • 56
    • 63049084008 scopus 로고    scopus 로고
    • The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials
    • Veyrat-Follet C., et al. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. J. Thromb. Haemost. 2009, 7:559-565.
    • (2009) J. Thromb. Haemost. , vol.7 , pp. 559-565
    • Veyrat-Follet, C.1
  • 57
    • 40749160810 scopus 로고    scopus 로고
    • Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial
    • The AMADEUS Investigators
    • Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008, 371:315-321. The AMADEUS Investigators.
    • (2008) Lancet , vol.371 , pp. 315-321
  • 58
    • 70449598269 scopus 로고    scopus 로고
    • Development of idraparinux and idrabiotaparinux for anticoagulant therapy
    • Harenberg J. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb. Haemost. 2009, 102:811-815.
    • (2009) Thromb. Haemost. , vol.102 , pp. 811-815
    • Harenberg, J.1
  • 59
    • 52449134037 scopus 로고    scopus 로고
    • Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy
    • Savi P., et al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J. Thromb. Haemost. 2008, 6:1697-1706.
    • (2008) J. Thromb. Haemost. , vol.6 , pp. 1697-1706
    • Savi, P.1
  • 60
    • 70350254762 scopus 로고    scopus 로고
    • New anticoagulants for atrial fibrillation
    • Sobieraj-Teague M., et al. New anticoagulants for atrial fibrillation. Semin. Thromb. Hemost. 2009, 35:515-524.
    • (2009) Semin. Thromb. Hemost. , vol.35 , pp. 515-524
    • Sobieraj-Teague, M.1
  • 61
    • 67649496320 scopus 로고    scopus 로고
    • Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026
    • Viskov C., et al. Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J. Thromb. Haemost. 2009, 7:1143-1151.
    • (2009) J. Thromb. Haemost. , vol.7 , pp. 1143-1151
    • Viskov, C.1
  • 62
    • 70349638447 scopus 로고    scopus 로고
    • AVE5026: a new hemisynthetic ultra low molecular weight heparin (ULMWH) with enriched anti-Xa activity and enhanced antithrombotic activity for management of cancer associated thrombosis
    • (Meeting Abstracts)
    • Hoppensteadt D., et al. AVE5026: a new hemisynthetic ultra low molecular weight heparin (ULMWH) with enriched anti-Xa activity and enhanced antithrombotic activity for management of cancer associated thrombosis. J. Clin. Oncol. 2008, 26(15 Suppl.):14653. (Meeting Abstracts).
    • (2008) J. Clin. Oncol. , vol.26 , Issue.15 SUPPL. , pp. 14653
    • Hoppensteadt, D.1
  • 63
    • 63049119668 scopus 로고    scopus 로고
    • AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery - TREK: a dose-ranging study
    • Lassen M.R., et al. AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery - TREK: a dose-ranging study. J. Thromb. Haemost. 2009, 7:566-572.
    • (2009) J. Thromb. Haemost. , vol.7 , pp. 566-572
    • Lassen, M.R.1
  • 64
    • 70350058915 scopus 로고    scopus 로고
    • Design and rationale of the evaluation of M118 in percutaneous coronary intervention (EMINENCE) trial
    • Melloni C., et al. Design and rationale of the evaluation of M118 in percutaneous coronary intervention (EMINENCE) trial. Am. Heart J. 2009, 158:726-733.
    • (2009) Am. Heart J. , vol.158 , pp. 726-733
    • Melloni, C.1
  • 65
    • 70449592260 scopus 로고    scopus 로고
    • M118-A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes
    • Kishimoto T.K., et al. M118-A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes. Thromb. Haemost. 2009, 102:900-906.
    • (2009) Thromb. Haemost. , vol.102 , pp. 900-906
    • Kishimoto, T.K.1
  • 66
    • 77956246541 scopus 로고    scopus 로고
    • Pharmacokinetics of M118, unfractionated heparin and enoxaparin sodium in normal and 5/6 nephrectomized uremic rats
    • Draganov D., et al. Pharmacokinetics of M118, unfractionated heparin and enoxaparin sodium in normal and 5/6 nephrectomized uremic rats. Toxicol. Lett. 2009, 189(Suppl. 1):S113-S1113.
    • (2009) Toxicol. Lett. , vol.189 , Issue.SUPPL. 1
    • Draganov, D.1
  • 67
    • 67849114034 scopus 로고    scopus 로고
    • A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation
    • Volovyk Z., et al. A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation. J. Thromb. Thrombolysis 2009, 28:132-139.
    • (2009) J. Thromb. Thrombolysis , vol.28 , pp. 132-139
    • Volovyk, Z.1
  • 68
    • 78649631067 scopus 로고    scopus 로고
    • A novel, rationally engineered heparin (M118) prevents thrombosis more effectively than unfractionated heparin in a canine model of deep arterial injury
    • Fier I., et al. A novel, rationally engineered heparin (M118) prevents thrombosis more effectively than unfractionated heparin in a canine model of deep arterial injury. J. Am. Coll. Cardiol. 2007, 49:379A-380A.
    • (2007) J. Am. Coll. Cardiol. , vol.49
    • Fier, I.1
  • 69
    • 70350536997 scopus 로고    scopus 로고
    • M118, a novel low-molecular weight heparin with decreased polydispersity leads to enhanced anticoagulant activity and thrombotic occlusion in ApoE knockout mice
    • Chakrabarti S., et al. M118, a novel low-molecular weight heparin with decreased polydispersity leads to enhanced anticoagulant activity and thrombotic occlusion in ApoE knockout mice. J. Thromb. Thrombolysis 2009, 28:394-400.
    • (2009) J. Thromb. Thrombolysis , vol.28 , pp. 394-400
    • Chakrabarti, S.1
  • 70
    • 77956253909 scopus 로고    scopus 로고
    • Lack of pharmacokinetic and pharmacodynamic interactions between M118, a novel low-molecular-weight-heparin and Eptifibatide in healthy subjects
    • Fier I.D., et al. Lack of pharmacokinetic and pharmacodynamic interactions between M118, a novel low-molecular-weight-heparin and Eptifibatide in healthy subjects. J. Clin. Pharmacol. 2009, 49:73.
    • (2009) J. Clin. Pharmacol. , vol.49 , pp. 73
    • Fier, I.D.1
  • 74
    • 70449701596 scopus 로고    scopus 로고
    • Therapeutic use of heparin beyond anticoagulation
    • Ludwig R.J. Therapeutic use of heparin beyond anticoagulation. Curr. Drug Discov. Technol. 2009, 6:281-289.
    • (2009) Curr. Drug Discov. Technol. , vol.6 , pp. 281-289
    • Ludwig, R.J.1
  • 75
    • 46749113163 scopus 로고    scopus 로고
    • The anti-inflammatory effects of heparin and related compounds
    • Young E. The anti-inflammatory effects of heparin and related compounds. Thromb. Res. 2008, 122:743-752.
    • (2008) Thromb. Res. , vol.122 , pp. 743-752
    • Young, E.1
  • 76
    • 77955482977 scopus 로고    scopus 로고
    • Antimetastatic activities of heparins and modified heparins. Experimental evidence
    • Borsig L. Antimetastatic activities of heparins and modified heparins. Experimental evidence. Thromb. Res. 2010, 125(Suppl. 2):S66-S71.
    • (2010) Thromb. Res. , vol.125 , Issue.SUPPL. 2
    • Borsig, L.1
  • 77
    • 34247637147 scopus 로고    scopus 로고
    • Heparanase: a target for drug discovery in cancer and inflammation
    • McKenzie E.A. Heparanase: a target for drug discovery in cancer and inflammation. Br. J. Pharmacol. 2007, 151:1-14.
    • (2007) Br. J. Pharmacol. , vol.151 , pp. 1-14
    • McKenzie, E.A.1
  • 78
    • 0034904048 scopus 로고    scopus 로고
    • Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis
    • Vlodavsky I., Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 2001, 108:341-347.
    • (2001) J. Clin. Invest. , vol.108 , pp. 341-347
    • Vlodavsky, I.1    Friedmann, Y.2
  • 79
    • 33746552708 scopus 로고    scopus 로고
    • Development of heparanase inhibitors for anti-cancer therapy
    • Miao H.-Q., et al. Development of heparanase inhibitors for anti-cancer therapy. Curr. Med. Chem. 2006, 13:2101-2111.
    • (2006) Curr. Med. Chem. , vol.13 , pp. 2101-2111
    • Miao, H.-Q.1
  • 80
    • 54949134525 scopus 로고    scopus 로고
    • PI-88: a novel inhibitor of angiogenesis
    • Kudchadkar R., et al. PI-88: a novel inhibitor of angiogenesis. Expert Opin. Investig. Drugs 2008, 17:1769-1776.
    • (2008) Expert Opin. Investig. Drugs , vol.17 , pp. 1769-1776
    • Kudchadkar, R.1
  • 81
    • 0037295612 scopus 로고    scopus 로고
    • The development of the novel angiogenesis inhibitor PI-88 as an anticancer drug
    • Ferro V., Don R. The development of the novel angiogenesis inhibitor PI-88 as an anticancer drug. Australas. Biotechnol. 2003, 13:38-39.
    • (2003) Australas. Biotechnol. , vol.13 , pp. 38-39
    • Ferro, V.1    Don, R.2
  • 82
    • 0035880995 scopus 로고    scopus 로고
    • Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides
    • Wall D., et al. Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides. Thromb. Res. 2001, 103:325-335.
    • (2001) Thromb. Res. , vol.103 , pp. 325-335
    • Wall, D.1
  • 83
    • 33749347624 scopus 로고    scopus 로고
    • A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors
    • Basche M., et al. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin. Cancer Res. 2006, 12:5471-5480.
    • (2006) Clin. Cancer Res. , vol.12 , pp. 5471-5480
    • Basche, M.1
  • 84
    • 0035985303 scopus 로고    scopus 로고
    • Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia
    • Rosenthal M.A., et al. Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia. Ann. Oncol. 2002, 13:770-776.
    • (2002) Ann. Oncol. , vol.13 , pp. 770-776
    • Rosenthal, M.A.1
  • 85
    • 53149138189 scopus 로고    scopus 로고
    • A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies
    • Chow L.Q., et al. A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer Chemother. Pharmacol. 2008, 63:65-74.
    • (2008) Cancer Chemother. Pharmacol. , vol.63 , pp. 65-74
    • Chow, L.Q.1
  • 86
    • 78649630192 scopus 로고    scopus 로고
    • Final results of a phase I study of daily PI-88 as a single agent and in combination with dacarbazine (D) in patients with metastatic melanoma
    • (Meeting Abstracts)
    • Millward M., et al. Final results of a phase I study of daily PI-88 as a single agent and in combination with dacarbazine (D) in patients with metastatic melanoma. J. Clin. Oncol. 2007, 25(Suppl. 18):8532. (Meeting Abstracts).
    • (2007) J. Clin. Oncol. , vol.25 , Issue.SUPPL. 18 , pp. 8532
    • Millward, M.1
  • 87
    • 77953974391 scopus 로고    scopus 로고
    • Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer
    • Khasraw M., et al. Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann. Oncol. 2009, 21:1302-1307.
    • (2009) Ann. Oncol. , vol.21 , pp. 1302-1307
    • Khasraw, M.1
  • 88
    • 38149089538 scopus 로고    scopus 로고
    • A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma
    • Lewis K.D., et al. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest. New Drugs 2008, 26:89-94.
    • (2008) Invest. New Drugs , vol.26 , pp. 89-94
    • Lewis, K.D.1
  • 89
    • 29744433264 scopus 로고    scopus 로고
    • Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88)
    • Karoli T., et al. Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88). J. Med. Chem. 2005, 48:8229-8236.
    • (2005) J. Med. Chem. , vol.48 , pp. 8229-8236
    • Karoli, T.1
  • 90
    • 34547092688 scopus 로고    scopus 로고
    • PI-88 and novel heparan sulfate mimetics inhibit angiogenesis
    • Ferro V., et al. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin. Thromb. Hemost. 2007, 33:557-568.
    • (2007) Semin. Thromb. Hemost. , vol.33 , pp. 557-568
    • Ferro, V.1
  • 91
    • 77952239575 scopus 로고    scopus 로고
    • The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy
    • Dredge K., et al. The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest. New Drugs 2009, 28:276-283.
    • (2009) Invest. New Drugs , vol.28 , pp. 276-283
    • Dredge, K.1
  • 94
    • 0038376613 scopus 로고    scopus 로고
    • Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders
    • van Horssen J., et al. Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol. 2003, 2:482-492.
    • (2003) Lancet Neurol. , vol.2 , pp. 482-492
    • van Horssen, J.1
  • 95
    • 0033572813 scopus 로고    scopus 로고
    • Interactions of Alzheimer amyloid-β peptides with glycosaminoglycans
    • McLaurin J.A., et al. Interactions of Alzheimer amyloid-β peptides with glycosaminoglycans. Eur. J. Biochem. 1999, 266:1101-1110.
    • (1999) Eur. J. Biochem. , vol.266 , pp. 1101-1110
    • McLaurin, J.A.1
  • 96
    • 0028278477 scopus 로고
    • Binding of heparan sulfate glycosaminoglycan to [beta]-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds
    • Leveugle B., et al. Binding of heparan sulfate glycosaminoglycan to [beta]-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds. Neuroreport 1994, 5:1389-1392.
    • (1994) Neuroreport , vol.5 , pp. 1389-1392
    • Leveugle, B.1
  • 97
    • 0028913416 scopus 로고
    • Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease
    • Kisilevsky R., et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat. Med. 1995, 1:143-148.
    • (1995) Nat. Med. , vol.1 , pp. 143-148
    • Kisilevsky, R.1
  • 98
    • 78649633926 scopus 로고    scopus 로고
    • Functional GAG mimetics as an approach for the treatment of amyloid diseases
    • Tremblay P., et al. Functional GAG mimetics as an approach for the treatment of amyloid diseases. Alzheimers Dement. 2005, 1(Suppl. 1):S2-S12.
    • (2005) Alzheimers Dement. , vol.1 , Issue.SUPPL. 1
    • Tremblay, P.1
  • 99
    • 34548689646 scopus 로고    scopus 로고
    • Alzhemed: a potential treatment for Alzheimers disease
    • Aisen P.S., et al. Alzhemed: a potential treatment for Alzheimers disease. Curr. Alzheimer Res. 2007, 4:473-478.
    • (2007) Curr. Alzheimer Res. , vol.4 , pp. 473-478
    • Aisen, P.S.1
  • 102
    • 33847133125 scopus 로고    scopus 로고
    • Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis
    • Gervais F., et al. Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging 2007, 28:537-547.
    • (2007) Neurobiol. Aging , vol.28 , pp. 537-547
    • Gervais, F.1
  • 103
    • 35748977086 scopus 로고    scopus 로고
    • Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau
    • Santa-Maria I., et al. Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. Mol. Neurodegener. 2007, 2:17.
    • (2007) Mol. Neurodegener. , vol.2 , pp. 17
    • Santa-Maria, I.1
  • 104
    • 33845388059 scopus 로고    scopus 로고
    • A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease
    • Aisen P.S., et al. A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006, 67:1757-1763.
    • (2006) Neurology , vol.67 , pp. 1757-1763
    • Aisen, P.S.1
  • 105
    • 61849185913 scopus 로고    scopus 로고
    • Recent developments in Alzheimer's disease therapeutics
    • Rafii M.S., Aisen P. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009, 7:7.
    • (2009) BMC Med. , vol.7 , pp. 7
    • Rafii, M.S.1    Aisen, P.2
  • 106
    • 65249138789 scopus 로고    scopus 로고
    • Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the Alzhemed™ (Tramiprosate) experience
    • Saumier D., et al. Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the Alzhemed™ (Tramiprosate) experience. J. Nutr. Health Aging 2009, 13:370-372.
    • (2009) J. Nutr. Health Aging , vol.13 , pp. 370-372
    • Saumier, D.1
  • 107
    • 75649105019 scopus 로고    scopus 로고
    • Current treatment and recent clinical research in Alzheimer's disease
    • Neugroschl J., Sano M. Current treatment and recent clinical research in Alzheimer's disease. Mt. Sinai J. Med. 2010, 77:3-16.
    • (2010) Mt. Sinai J. Med. , vol.77 , pp. 3-16
    • Neugroschl, J.1    Sano, M.2
  • 108
    • 33750100708 scopus 로고    scopus 로고
    • Eprodisate sodium
    • Revill P., et al. Eprodisate sodium. Drugs Future 2006, 31:576-578.
    • (2006) Drugs Future , vol.31 , pp. 576-578
    • Revill, P.1
  • 109
    • 0033548474 scopus 로고    scopus 로고
    • The heparin/heparan sulfate-binding site on apo-serum Amyloid A
    • Ancsin J.B., Kisilevsky R. The heparin/heparan sulfate-binding site on apo-serum Amyloid A. J. Biol. Chem. 1999, 274:7172-7181.
    • (1999) J. Biol. Chem. , vol.274 , pp. 7172-7181
    • Ancsin, J.B.1    Kisilevsky, R.2
  • 110
    • 34250019930 scopus 로고    scopus 로고
    • Proteoglycans and amyloidogenic proteins in peripheral amyloidosis
    • Gervais F., et al. Proteoglycans and amyloidogenic proteins in peripheral amyloidosis. Curr. Med. Chem. Immunol. Endocr. Metab. Agents 2003, 3:361-370.
    • (2003) Curr. Med. Chem. Immunol. Endocr. Metab. Agents , vol.3 , pp. 361-370
    • Gervais, F.1
  • 111
    • 0034110874 scopus 로고    scopus 로고
    • The relation of proteoglycans, serum amyloid P and Apo E to amyloidosis current status, 2000
    • Kisilevsky R. The relation of proteoglycans, serum amyloid P and Apo E to amyloidosis current status, 2000. Amyloid 2000, 7:23-25.
    • (2000) Amyloid , vol.7 , pp. 23-25
    • Kisilevsky, R.1
  • 112
    • 78649632515 scopus 로고    scopus 로고
    • Clinicaltrials.gov. (2002) A phase II/III study of the safety and efficacy of NC-503 in patients suffering from secondary (AA) amyloidosis.
    • Clinicaltrials.gov. (2002) A phase II/III study of the safety and efficacy of NC-503 in patients suffering from secondary (AA) amyloidosis (). ctgov:NCT00035334.
  • 113
    • 34249992082 scopus 로고    scopus 로고
    • Eprodisate for the treatment of renal disease in AA amyloidosis
    • Dember L.M., et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N. Engl. J. Med. 2007, 356:2349-2360.
    • (2007) N. Engl. J. Med. , vol.356 , pp. 2349-2360
    • Dember, L.M.1
  • 114
    • 50949108535 scopus 로고    scopus 로고
    • Eprodisate in amyloid A amyloidosis: a novel therapeutic approach?
    • Manenti L., et al. Eprodisate in amyloid A amyloidosis: a novel therapeutic approach?. Expert Opin. Pharmacother. 2008, 9:2175-2180.
    • (2008) Expert Opin. Pharmacother. , vol.9 , pp. 2175-2180
    • Manenti, L.1
  • 116
    • 79956267087 scopus 로고    scopus 로고
    • Small molecule inhibitors of glycosaminoglycan biosynthesis as substrate optimization therapy for the mucopolysaccharidoses
    • Brown J., et al. Small molecule inhibitors of glycosaminoglycan biosynthesis as substrate optimization therapy for the mucopolysaccharidoses. Proceedings of the Lysosomal Disease Network WORLD Symposium, vol. 99 2010, S12-S112.
    • (2010) Proceedings of the Lysosomal Disease Network WORLD Symposium, vol. 99
    • Brown, J.1
  • 117
    • 77956485588 scopus 로고    scopus 로고
    • Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer
    • Casu B., et al. Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol. 2010, 29:442-452.
    • (2010) Matrix Biol. , vol.29 , pp. 442-452
    • Casu, B.1
  • 118
    • 34447287858 scopus 로고    scopus 로고
    • Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate
    • Vlodavsky I., et al. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr. Pharm. Des. 2007, 13:2057-2073.
    • (2007) Curr. Pharm. Des. , vol.13 , pp. 2057-2073
    • Vlodavsky, I.1
  • 119
    • 33845357884 scopus 로고    scopus 로고
    • Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin
    • Mousa S.A., et al. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb. Haemost. 2006, 96:816-821.
    • (2006) Thromb. Haemost. , vol.96 , pp. 816-821
    • Mousa, S.A.1
  • 120
    • 70449122133 scopus 로고    scopus 로고
    • Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells
    • Lee D.Y., et al. Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells. Pharm. Res. 2009, 26:2667-2676.
    • (2009) Pharm. Res. , vol.26 , pp. 2667-2676
    • Lee, D.Y.1
  • 122
    • 85056565879 scopus 로고    scopus 로고
    • Antitumor activity of EP80061, a small-glyco drug in preclinical studies
    • Serina G., et al. Antitumor activity of EP80061, a small-glyco drug in preclinical studies. Proceedings of the AACR meeting 2010.
    • (2010) Proceedings of the AACR meeting
    • Serina, G.1
  • 127
    • 33646232965 scopus 로고    scopus 로고
    • Regenerating agents (RGTAs): a new therapeutic approach
    • Barritault D., Caruelle J.P. Regenerating agents (RGTAs): a new therapeutic approach. Ann. Pharm. Fr. 2006, 64:135-144.
    • (2006) Ann. Pharm. Fr. , vol.64 , pp. 135-144
    • Barritault, D.1    Caruelle, J.P.2
  • 128
    • 0026592363 scopus 로고
    • Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF
    • Tardieu M., et al. Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF. J. Cell. Physiol. 1992, 150:194-203.
    • (1992) J. Cell. Physiol. , vol.150 , pp. 194-203
    • Tardieu, M.1
  • 129
    • 0030200049 scopus 로고    scopus 로고
    • Heparin-like polymers derived from dextran enhance colonic anastomosis resistance to leakage
    • Meddahi A., et al. Heparin-like polymers derived from dextran enhance colonic anastomosis resistance to leakage. J. Biomed. Mater. Res. 1996, 31:293-297.
    • (1996) J. Biomed. Mater. Res. , vol.31 , pp. 293-297
    • Meddahi, A.1
  • 130
    • 25444472167 scopus 로고    scopus 로고
    • A synthetic glycosaminoglycan mimetic minds vascular endothelial growth factor and modulates angiogenesis
    • Rouet V., et al. A synthetic glycosaminoglycan mimetic minds vascular endothelial growth factor and modulates angiogenesis. J. Biol. Chem. 2005, 280:32792-32800.
    • (2005) J. Biol. Chem. , vol.280 , pp. 32792-32800
    • Rouet, V.1
  • 131
    • 0030028218 scopus 로고    scopus 로고
    • FGF protection and inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives
    • Meddahi A., et al. FGF protection and inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives. Int. J. Biol. Macromol. 1996, 18:141-145.
    • (1996) Int. J. Biol. Macromol. , vol.18 , pp. 141-145
    • Meddahi, A.1
  • 132
    • 0029586998 scopus 로고
    • Inhibition by dextran derivatives of FGF-2 plasmin-mediated degradation
    • Meddahi A., et al. Inhibition by dextran derivatives of FGF-2 plasmin-mediated degradation. Biochimie 1995, 77:703-706.
    • (1995) Biochimie , vol.77 , pp. 703-706
    • Meddahi, A.1
  • 133
    • 0034703008 scopus 로고    scopus 로고
    • Human plasmin enzymatic activity is inhibited by chemically modified dextrans
    • Ledoux D., et al. Human plasmin enzymatic activity is inhibited by chemically modified dextrans. J. Biol. Chem. 2000, 275:29383-29390.
    • (2000) J. Biol. Chem. , vol.275 , pp. 29383-29390
    • Ledoux, D.1
  • 134
    • 33748039731 scopus 로고    scopus 로고
    • Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro
    • Rouet V., et al. Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro. J. Biomed. Mater. Res. A 2006, 78:792-797.
    • (2006) J. Biomed. Mater. Res. A , vol.78 , pp. 792-797
    • Rouet, V.1
  • 135
    • 70350666256 scopus 로고    scopus 로고
    • Matrix therapy in regenerative medicine, a new approach to chronic wound healing
    • Barbier-Chassefière V., et al. Matrix therapy in regenerative medicine, a new approach to chronic wound healing. J. Biomed. Mater. Res. A 2009, 90:641-647.
    • (2009) J. Biomed. Mater. Res. A , vol.90 , pp. 641-647
    • Barbier-Chassefière, V.1
  • 136
    • 0028076068 scopus 로고
    • New approaches to tissue regeneration and repair
    • Meddahi A., et al. New approaches to tissue regeneration and repair. Pathol. Res. Pract. 1994, 190:923-928.
    • (1994) Pathol. Res. Pract. , vol.190 , pp. 923-928
    • Meddahi, A.1
  • 137
    • 0029881016 scopus 로고    scopus 로고
    • Modulation of cranial bone healing with a heparin-like dextran derivative
    • Albo D., et al. Modulation of cranial bone healing with a heparin-like dextran derivative. J. Craniofac. Surg. 1996, 7:19-22.
    • (1996) J. Craniofac. Surg. , vol.7 , pp. 19-22
    • Albo, D.1
  • 138
    • 0029585215 scopus 로고
    • Heparan-like molecules induce the repair of skull defects
    • Blanquaert F., et al. Heparan-like molecules induce the repair of skull defects. Bone 1995, 17:499-506.
    • (1995) Bone , vol.17 , pp. 499-506
    • Blanquaert, F.1
  • 139
    • 0033738410 scopus 로고    scopus 로고
    • New agents for the treatment of infarcted myocardium
    • Yamauchi H., et al. New agents for the treatment of infarcted myocardium. FASEB J. 2000, 14:2133-2134.
    • (2000) FASEB J. , vol.14 , pp. 2133-2134
    • Yamauchi, H.1
  • 140
    • 0037024112 scopus 로고    scopus 로고
    • Heparin-like polymer improved healing of gastric and colic ulceration
    • Meddahi A., et al. Heparin-like polymer improved healing of gastric and colic ulceration. J. Biomed. Mater. Res. 2002, 60:497-501.
    • (2002) J. Biomed. Mater. Res. , vol.60 , pp. 497-501
    • Meddahi, A.1
  • 141
    • 0141535210 scopus 로고    scopus 로고
    • A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers
    • Escartin Q., et al. A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers. FASEB J. 2003, 17:644-651.
    • (2003) FASEB J. , vol.17 , pp. 644-651
    • Escartin, Q.1
  • 142
    • 0036323139 scopus 로고    scopus 로고
    • Glycosaminoglycan mimetics (RGTA) modulate adult skeletal muscle satellite cell proliferation in vitro
    • Papy-Garcia D., et al. Glycosaminoglycan mimetics (RGTA) modulate adult skeletal muscle satellite cell proliferation in vitro. J. Biomed. Mater. Res. 2002, 62:46-55.
    • (2002) J. Biomed. Mater. Res. , vol.62 , pp. 46-55
    • Papy-Garcia, D.1
  • 143
    • 0344845037 scopus 로고    scopus 로고
    • Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis
    • Schonberger O., et al. Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis. Biochem. Biophys. Res. Commun. 2003, 312:473-479.
    • (2003) Biochem. Biophys. Res. Commun. , vol.312 , pp. 473-479
    • Schonberger, O.1
  • 144
    • 0042854755 scopus 로고    scopus 로고
    • A novel generation of heparan sulfate mimetics for the treatment of prion diseases
    • Adjou K.T., et al. A novel generation of heparan sulfate mimetics for the treatment of prion diseases. J. Gen. Virol. 2003, 84:2595-2603.
    • (2003) J. Gen. Virol. , vol.84 , pp. 2595-2603
    • Adjou, K.T.1
  • 145
    • 20944439207 scopus 로고    scopus 로고
    • A synthetic glycosaminoglycan mimetic (RGTA) modifies natural glycosaminoglycan species during myogenesis
    • Barbosa I., et al. A synthetic glycosaminoglycan mimetic (RGTA) modifies natural glycosaminoglycan species during myogenesis. J. Cell Sci. 2005, 118:253-264.
    • (2005) J. Cell Sci. , vol.118 , pp. 253-264
    • Barbosa, I.1
  • 146
    • 0028889539 scopus 로고
    • Effect of a substituted dextran on reinnervation during regeneration of adult rat skeletal muscle
    • Aamiri A., et al. Effect of a substituted dextran on reinnervation during regeneration of adult rat skeletal muscle. C. R. Acad. Sci. III. Sci. Vie 1995, 318:1037-1044.
    • (1995) C. R. Acad. Sci. III. Sci. Vie , vol.318 , pp. 1037-1044
    • Aamiri, A.1
  • 147
    • 20444420498 scopus 로고    scopus 로고
    • Nondegradative sulfation of polysaccharides. Synthesis and structure characterization of biologically active heparan sulfate mimetics
    • Papy-Garcia D., et al. Nondegradative sulfation of polysaccharides. Synthesis and structure characterization of biologically active heparan sulfate mimetics. Macromolecules 2005, 38:4647-4654.
    • (2005) Macromolecules , vol.38 , pp. 4647-4654
    • Papy-Garcia, D.1
  • 148
    • 77952544052 scopus 로고    scopus 로고
    • Glycosaminoglycan mimetics trigger IP3-dependent intracellular calcium release in myoblasts
    • Martelly I., et al. Glycosaminoglycan mimetics trigger IP3-dependent intracellular calcium release in myoblasts. Matrix Biol. 2010, 29:317-329.
    • (2010) Matrix Biol. , vol.29 , pp. 317-329
    • Martelly, I.1
  • 149
    • 58149163003 scopus 로고    scopus 로고
    • Significant reduction in neural adhesions after administration of the regenerating agent OTR4120, a synthetic glycosaminoglycan mimetic, after peripheral nerve injury in rats
    • Zuijdendorp H.M., et al. Significant reduction in neural adhesions after administration of the regenerating agent OTR4120, a synthetic glycosaminoglycan mimetic, after peripheral nerve injury in rats. J. Neurosurg. 2008, 109:967-973.
    • (2008) J. Neurosurg. , vol.109 , pp. 967-973
    • Zuijdendorp, H.M.1
  • 150
    • 33845485024 scopus 로고    scopus 로고
    • RGTA OTR4120, a heparan sulfate mimetic, is a possible long-term active agent to heal burned skin
    • Garcia-Filipe S., et al. RGTA OTR4120, a heparan sulfate mimetic, is a possible long-term active agent to heal burned skin. J. Biomed. Mater. Res. A 2007, 80:75-84.
    • (2007) J. Biomed. Mater. Res. A , vol.80 , pp. 75-84
    • Garcia-Filipe, S.1
  • 151
    • 70350638975 scopus 로고    scopus 로고
    • Stimulated neovascularization, inflammation resolution and collagen maturation in healing rat cutaneous wounds by a heparan sulfate glycosaminoglycan mimetic, OTR4120
    • Tong M., et al. Stimulated neovascularization, inflammation resolution and collagen maturation in healing rat cutaneous wounds by a heparan sulfate glycosaminoglycan mimetic, OTR4120. Wound Repair Regen. 2009, 17:840-852.
    • (2009) Wound Repair Regen. , vol.17 , pp. 840-852
    • Tong, M.1
  • 152
    • 0037114256 scopus 로고    scopus 로고
    • 11, a heparan sulfate mimetic polymer, efficient on muscle regeneration
    • 11, a heparan sulfate mimetic polymer, efficient on muscle regeneration. J. Biomed. Mater. Res. 2002, 62:525-531.
    • (2002) J. Biomed. Mater. Res. , vol.62 , pp. 525-531
    • Meddahi, A.1
  • 153
    • 45249101320 scopus 로고    scopus 로고
    • Pilot study of a new matrix therapy agent (RGTA OTR4120®) in treatment-resistant corneal ulcers and corneal dystrophy
    • Chebbi C.K., et al. Pilot study of a new matrix therapy agent (RGTA OTR4120®) in treatment-resistant corneal ulcers and corneal dystrophy. J. Fr. Opthalmol. 2008, 31:465-471.
    • (2008) J. Fr. Opthalmol. , vol.31 , pp. 465-471
    • Chebbi, C.K.1
  • 155
    • 78649636504 scopus 로고    scopus 로고
    • Neutralization of hemorrhagic and antithrombotic activities of heparins by a novel salicylamide derivative
    • (Meeting Abstracts 1)
    • Kuziej J., et al. Neutralization of hemorrhagic and antithrombotic activities of heparins by a novel salicylamide derivative. FASEB J. 2009, 23:566-569. (Meeting Abstracts 1).
    • (2009) FASEB J. , vol.23 , pp. 566-569
    • Kuziej, J.1
  • 156
    • 78649632442 scopus 로고    scopus 로고
    • Neutralization of the anticoagulant and anti-Xa effects of fondaparinux and idraparinux by a novel synthetic antagonist. Pharmacologic implications
    • (Meeting Abstracts 1)
    • Fareed J., et al. Neutralization of the anticoagulant and anti-Xa effects of fondaparinux and idraparinux by a novel synthetic antagonist. Pharmacologic implications. FASEB J. 2008, 22:1117-1118. (Meeting Abstracts 1).
    • (2008) FASEB J. , vol.22 , pp. 1117-1118
    • Fareed, J.1
  • 158
    • 13344294985 scopus 로고    scopus 로고
    • The synthesis of well-defined heparin and heparan sulfate fragments
    • Codée J.D.C., et al. The synthesis of well-defined heparin and heparan sulfate fragments. Drug Discov Today: Technol. 2004, 1:317-326.
    • (2004) Drug Discov Today: Technol. , vol.1 , pp. 317-326
    • Codée, J.D.C.1
  • 159
    • 84896702944 scopus 로고    scopus 로고
    • Small molecule inhibitors of glycosaminoglycan biosynthesisas substrate optimization therapy for the mucopolysaccharidoses
    • Brown J., et al. Small molecule inhibitors of glycosaminoglycan biosynthesisas substrate optimization therapy for the mucopolysaccharidoses. Mol. Genet. Metab. 2010, 99:S12-S112.
    • (2010) Mol. Genet. Metab. , vol.99
    • Brown, J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.